Cell Lysis & Disruption Market Size, Share & Trends Analysis Report By Application (Protein Isolation, Downstream Processing), By Cell Type, By Technique, By Product, By End Use, And Segment Forecasts, 2021 - 2028

Report Overview

The global cell lysis & disruption market size was valued at USD 4.09 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.35% from 2021 to 2028. High adoption of biotechnology processes in bio-services, agricultural, and pharmaceutical industries coupled with a rise in the adoption of gene expression protocols has majorly driven the growth of this market. The ongoing COVID-19 pandemic has positively impacted the market growth. An increase in R&D activities for the development of a vaccine for COVID-19 has augmented the demand for technologies used for bioprocessing, including cell lysis & disruption. Owing to this, key companies shifted their focus on offering bioprocessing-related solutions, in turn, capturing substantial revenue growth.

Growing investments by several organizations including government, as well as private, towards R&D related to biotechnological processes and academics are expected to further drive the market significantly. In addition, a rise in the prevalence of disorders and high demand for novel therapeutics are expected to propel market growth.

The expansion in the biopharmaceutical industry would provide new growth avenues to the market, as retrieval and purification of biopharmaceuticals involve cell lysis & disruption. Moreover, the adoption of biotech processes in pharmaceutical, agricultural, and bio-services industries is expected to drive the market as cell lysis holds substantial importance in the course of the bioprocess.

The rise in demand for efficient tumor tissue dissociation equipment has led to the development of novel products based on microfluidics. Microfluidic devices are found to be useful in the efficient dissociation of tumor tissues in single cells and thereby enhance cell recovery with respect to number and purity.

Technique Insights

In 2020, the reagent-based method segment accounted for the largest revenue share of more than 65%. These methods do not destroy the biological activity of the final products, are mild, and ideally suited for laboratory samples. The mentioned facts make them a suitable choice for laboratory usage, consequently leading to their dominance in terms of market share throughout the forecast period.

Physical disruption methods were traditionally adopted by major players operating in this space for the extraction of intracellular contents. However, the adoption of these methods has relatively decreased currently owing to the requirement for expensive and cumbersome equipment. Owing to the presence of variability in the apparatus, physical disruption methods are difficult to repeat, thus reducing their market penetration.

Product Insights

The reagents and consumables segment accounted for the largest revenue share of more than 67% in 2020. Enzymes dominated the reagents and consumables segment and are expected to grow a significant CAGR during the forecast period. Factors attributing to the estimated share include an application for the selective product release, and controlled lysis as these provide biological specificity to the process.

Owing to the enzyme specificity, different kits and enzymes are available for bacterial, plant, yeast, and mammalian samples. These enzymes are commercially available in a variety of forms. Major brands include but are not limited to Alfa Aesar, Millipore Sigma, MP Biochemicals LLC, Pierce Biotechnology Inc., and Promega Corp.

Cell Type Insights

The mammalian cells segment accounted for the major revenue share of more than 45% in 2020 and is expected to remain dominant throughout the forecast period. This is because mammalian culture systems are extensively used during the bio-manufacturing of viral vaccines, therapeutic proteins, and other recombinant products.

In addition, the adoption of 3D mammalian culture systems stem cell and cancer research is anticipated to boost segment growth. As the efficiency of reagents varies with the type of cell used, key players have developed reagents that work specifically on mammalian cells.

For instance, Merck Millipore provides a range of mammalian lysis reagents that are utilized for the preparation of mammalian phosphorylated, cytosolic, and nuclear proteins. Some products are CytoBuster protein extraction reagent, NucBuster protein extraction kit, PhosphoSafe extraction reagent, and ProteoExtract kits.

Application Insights

The protein isolation segment accounted for the highest revenue share of more than 32% in 2020. The major application areas of protein isolation include proteomics, western blotting, and immunoprecipitation. Demand for efficient and rapid lysis techniques that can extract the proteins with minimal protein breakdown or oxidation is expected to fuel segment growth.

Viscosity, which is resultant of the cell debris and genomic contamination is another challenge that needs to be addressed, pronouncing research in this segment. The development of advanced bioprocessing reagents and equipment that can readily complement the established disruption procedures are anticipated to propel growth in the market.

Moreover, the rise in demand for industrial biotechnology products, such as hormones, antibodies, enzymes, antibiotics, and vaccines, has driven the market for downstream processing. The ongoing efforts for the COVID-19 vaccine development have also supplemented the market growth. Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen are some of the approved vaccines for COVID-19.

End-use Insights

The pharmaceutical & biotechnology companies segment accounted for the largest market share of more than 35% in 2020. This is due to the presence of a large number of biotechnology companies that explore molecular biology, and bioprocess techniques, thus employing cell lysis protocols. The rise in demand for biopharmaceuticals is expected to significantly drive the segment growth over the years to come.

The safety and efficacy offered by biopharmaceutical products, along with their ability to tackle clinical conditions that were untreatable previously, have driven their demand. Therefore, pharmaceutical organizations are increasingly shifting toward manufacturing biopharmaceutical products, which, in turn, would drive the market. The presence of several protocols for tumorigenicity testing and research has led to substantial usage of cell disruption methods in the biospecimen banking facilities. Clinical research carried out for drug development is expected to drive potential growth in the coming years.

Regional Insights

In 2020, North America accounted for the largest revenue share of more than 41% with Europe following closely. The presence of government initiatives in the U.S. and Canada that support molecular biology research, precision medicine, and cancer research is attributed to the market dominance of this region. High private, as well as public, investments in target therapeutics and novel drug discovery of various complicated and rare diseases, are anticipated to further drive the demand.

However, Asia Pacific is poised to witness the fastest CAGR over the forecast period. This growth can be credited to the increasing interest of key players in emerging markets of the APAC region to reap higher profits. In Asian countries, such as Japan and China, rapid adoption of technological innovations and regulatory environment that supports innovation further influences market growth. In addition, the rapidly emerging field of personalized cancer medicine in Asian countries is anticipated to positively impact the market growth.

Key Companies & Market Share Insights

Most of the key companies focus on various business expansion strategies, such as novel product launches, acquisitions, and collaborations, to enhance their market position. For instance, in January 2021, Thermo Fisher Scientific, Inc. acquired Henogen S.A., the viral vector manufacturing business of Novasep. This expanded the company’s capabilities for gene and cell therapies & vaccines as well as enhanced cell lysis and disruption business as it is a part of manufacturing workflow. Key players operating in the global cell lysis & disruption market include

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• F. Hoffmann-La Roche Ltd.

• Qiagen NV

• Becton Dickinson & Company (BD)

• Danaher Corp.

• Bio-Rad Laboratories, Inc.

• Miltenyi Biotec GmbH

• Claremont BioSolutions, LLC

• Microfluidics International Corp.

• Parr Instrument Company

• BioVision, Inc.

• Covaris, Inc.

• Qsonica LLC 

Cell Lysis & Disruption Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2028. For the purpose of this study, Grand View Research has segmented the global cell lysis & disruption market report on the basis of technique, product, cell type, application, end use, and region:

• Technique Outlook (Revenue, USD Million, 2018 - 2028)

  • Reagent-Based

    • Detergent

    • Enzymatic

  • Physical Disruption

    • Mechanical Homogenization

    • Ultrasonic Homogenization

    • Pressure Homogenization

    • Temperature Treatments

• Product Outlook (Revenue, USD Million, 2018 - 2028)

  • Instruments

    • High Pressure Homogenizers

    • Sonicator

    • French Press

    • Microfluidizer

    • Bead Mill

    • Other Instruments

  • Reagents & Consumables

    • Enzymes

    • Detergent Solutions

      • Ionic detergent

      • Nonionic detergent

      • Zwitterionic detergent

    • Kits & Reagents

• Cell Type Outlook (Revenue, USD Million, 2018 - 2028)

  • Mammalian cells

  • Bacterial cells

  • Yeast/Algae/Fungi

  • Plant cells

• Application Outlook (Revenue, USD Million, 2018 - 2028)

  • Protein Isolation

  • Downstream Processing

  • Cell organelle isolation

  • Nucleic acid isolation

• Outlook, by End Use (Revenue, USD Million, 2018 - 2028)

  • Academic & Research Institutes

  • Hospitals & Diagnostic Labs

  • Cell Banks

  • Pharmaceutical & Biotechnology Companies

• Region Outlook (Revenue, USD Million, 2018 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • China

    • Japan

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia